Healthcare

Onconova Therapeutics (NASDAQ: ONTX) CEO Interview Series

February 1, 2019 The Wall Street Analyzer Comments Off

Onconova Therapeutics (NASDAQ: ONTX) CEO: Steve Fruchtman THIS INTERVIEW HAS EXPIRED

MediXall Group (OTCQB: MDXL) CEO Interview Series

January 30, 2019 The Wall Street Analyzer Comments Off

MediXall Group (OTCQB: MDXL) CEO: Michael Swartz SVP Marketing: Vincent Caputo THIS INTERVIEW HAS EXPIRED

Citius Pharmaceuticals to Present at NobleCon15 Investor Conference

January 26, 2019 The Wall Street Analyzer Comments Off

Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 28th at 10:00am Eastern Standard Timein Studio 2. […]

Generex Biotechnology (OTC: GNBT) CEO Interview

January 22, 2019 The Wall Street Analyzer Comments Off

Generex Biotechnology (OTC: GNBT) CEO: Joe Moscato THIS INTERVIEW HAS EXPIRED

DURECT Corporation (NASDAQ:DRRX) President and CEO: Jim Brown

December 4, 2018 The Wall Street Analyzer Comments Off

DURECT Corporation (NASDAQ:DRRX) President and CEO: Jim Brown THIS INTERVIEW HAS EXPIRED

Eyenovia, Inc (NASDAQ: EYEN) Interview with Dr. Sean Ianchulev

September 18, 2018 The Wall Street Analyzer Comments Off

Eyenovia, Inc (NASDAQ: EYEN) CEO: Dr. Sean Ianchulev THIS INTERVIEW HAS EXPIRED

Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth

August 8, 2018 The Wall Street Analyzer Comments Off

Company’s Fourth Consecutive Quarter of Record Revenue and Third Consecutive Quarter with Year-Over-Year Revenue Growth Exceeding 20% […]

Contravir (NASDAQ: CTRV) Interview with CEO James Sapirstein in which he discusses recent funding and CRV431 progress

July 9, 2018 The Wall Street Analyzer Comments Off

Contravir Pharmaceuticals (NASDAQ: CTRV) CEO: James Sapirstein INTERVIEW TRANSCRIPTS: WSA: Good day from Wall Street, this is Juan Costello Senior Analyst with the Wall Street Analyzer. Joining us today is James Sapirstein CEO for […]

Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress

May 23, 2018 The Wall Street Analyzer Comments Off

NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) — Jeff Baxter, President and CEO of VBI Vaccines Inc. (NASDAQ:VBIV), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, took time to update WSA’s investor […]

Erytech (NASDAQ: ERYP) Management Interview

May 17, 2018 The Wall Street Analyzer Comments Off

Management Interview […]

Featured Interviews

ClearBlue Technologies International (TSXV: CBLU)(OTC: CBUTF)

December 27, 2023 0

Clear Blue Technologies International, the leader in Smart Power, was founded on a vision of delivering clean, managed, “wireless power” to meet the global need for reliable, low-cost, solar and hybrid power for lighting, telecom, security, Internet of Things devices, and other mission-critical systems. Today, Clear Blue is working with its customers “On the Road to Zero Diesel”. […]

Featured Interviews

Platinex Inc. (CSE: PTX)(OTCQB: PANXF)

December 11, 2023 0

Platinex Inc. creates shareholder value through the opportunistic acquisition and advancement of high-quality projects in prolific Ontario mining camps. Current assets include a 100% ownership interest in the W2 Copper-Nickel-PGE Project near the “Ring of Fire” in northern Ontario and a 75% interest in the South Timmins Mining joint venture with Fancamp Exploration, which is focused on gold exploration along the Ridout-Tyrell Deformation Zone near IAMGOLD’s Côté Gold operation in the southwest Abitibi. […]

Onconova Therapeutics (NASDAQ: ONTX) CEO Interview Series

MediXall Group (OTCQB: MDXL) CEO Interview Series

Citius Pharmaceuticals to Present at NobleCon15 Investor Conference

Generex Biotechnology (OTC: GNBT) CEO Interview

DURECT Corporation (NASDAQ:DRRX) President and CEO: Jim Brown

Eyenovia, Inc (NASDAQ: EYEN) Interview with Dr. Sean Ianchulev

Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth

Contravir (NASDAQ: CTRV) Interview with CEO James Sapirstein in which he discusses recent funding and CRV431 progress

Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress

Erytech (NASDAQ: ERYP) Management Interview

Prodex, Inc (NASDAQ: PDEX)

Client Testimonials: